BMI1 is a therapeutic target in recurrent medulloblastoma.

Medulloblastoma (MB) is the most frequent malignant pediatric brain tumor, representing 20% of newly diagnosed childhood central nervous system malignancies. This work described the epigenetic regulator BMI1 as a novel therapeutic target for the treatment of recurrent human Group 3 MB, a childhood brain tumor for which there is virtually no treatment option beyond palliation. To learn more about BMI1 as a novel therapeutic target, read the full article from Dr. Sheila Singh's lab:

https://www.ncbi.nlm.nih.gov/pubmed/30348991